The ROAD 2.0 to Sustainable Medication Use: Redispensing Unused Oral Anticancer Drugs
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 20, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
The ROAD 2.0 trial is studying a new way to handle unused oral anticancer medications. The researchers want to see if giving these unused drugs back to the pharmacy can save money and help the environment, compared to just throwing them away. They will be looking at how effective this redispensing process is and what benefits it brings.
Anyone diagnosed with cancer who takes oral anticancer medications that can be stored at room temperature may be eligible to participate. If you join the study, you will receive your medication in a special sealed bag. During your next hospital visit, you can return any unused medication to the pharmacy. This trial is open to patients of all ages and both men and women. It’s important to note that participants should be able to understand Dutch or English, as this is necessary for communication throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients of all ages
- • A clinical diagnosis of cancer using an oral anticancer drug that requires storage at room temperature according to the Summary of Product Characteristics (SmPC).
- Exclusion Criteria:
- • Patients that do not understand the Dutch or English language, in written or spoken.
- • Patients receiving prescriptions that contain an amount of tablets that deviates from the regular package size, resulting in the pharmacy dispensing an opened package
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported